A U.S. review panel on Friday recommended loosening restrictions on all but one of a buzzy class of peptides, dismissing protests from medical experts who say none are well studied enough to justify wide access.
This article was originally published by MedicalXpress. For more details, images, and references:
Read Full Original Article ↗